Topical Cream for Mastocytosis

This trial explores a new skin cream for treating skin lesions caused by mastocytosis, a condition where too many mast cells accumulate in the skin. The cream combines three ingredients: one blocks histamine, another reduces inflammation, and a third prevents mast cells from releasing their contents. Individuals with confirmed skin mastocytosis who have not recently used certain skin treatments might be eligible to join. The trial aims to determine if this cream is effective and easy to tolerate. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you stop using certain medications, such as topical or systemic corticosteroids, and other systemic preparations like cyclosporine and methotrexate, at least 1 month before joining. If you're on these medications, you'll need to stop them before participating.

Research has shown that the topical cream for mastocytosis, containing sodium cromolyn, diphenhydramine, and trolamine salicylate, appears safe. Sodium cromolyn prevents allergic reactions by stopping certain cells from releasing chemicals. Diphenhydramine, an antihistamine, reduces itching and swelling. Trolamine salicylate reduces inflammation.

Researchers are excited about this new topical cream for mastocytosis because it combines three active ingredients that work together in a unique way. Unlike standard treatments, which often focus on oral medications to manage symptoms, this cream directly targets the skin, where mastocytosis symptoms often manifest. Sodium cromolyn in the cream inhibits mast cell degranulation, diphenhydramine acts as an antihistamine, and trolamine salicylate reduces inflammation. This targeted, multi-faceted approach has the potential to provide more effective and localized relief, minimizing systemic side effects often seen with oral treatments.

Research has shown that sodium cromolyn, an ingredient in the topical cream studied in this trial, helps manage mastocytosis symptoms by preventing certain cells from releasing inflammation-causing substances. However, disodium cromoglycate, a similar compound, has not been effective for skin symptoms of cutaneous mastocytosis. Diphenhydramine, another ingredient, is an antihistamine that reduces itching and discomfort. Trolamine salicylate, also in the cream, acts as an anti-inflammatory, reducing swelling and pain. While each ingredient offers benefits, the trial continues to study the cream's overall effectiveness in treating skin lesions from mastocytosis.²³⁴⁵⁶